RT @AdelaCastro222: The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #
Tweet Content
The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims https://t.co/vxa05r0GvS
Show on Archive Page
On
Display in Search Results
On
PDQ
Off